Cybersecurity Firm Plurilock Signs $2.45M Software Licensing Deal with Nasdaq-Listed Semiconductor Manufacturer

Plurilock Security signed a 2-year software licensing agreement worth C$2.45 million with a Nasdaq-listed semiconductor manufacturer. NanoViricides is gearing up to tackle multiple viral threats with Phase 2 trials for its broad-spectrum antiviral NV-378. Tiziana Life Sciences has dosed the first patient in a Phase 2 clinical trial testing its intranasal drug candidate foralumab in patients with early Alzheimer’s disease. 1911 Gold Corp began a 2,200-metre diamond drilling program at its Ogama-Rockland gold deposit in Manitoba. Protalix Biotherapeutics entered into a collaboration and option agreement with Secarna Pharmaceuticals to jointly develop new antisense oligonucleotide therapies targeting rare kidney diseases. Tertiary Minerals PLC announced that Patrick Cheetham will transition to non-executive chairman. Seeing Machines Ltd launched a new technical paper series on non-fatigue driver impairment, beginning with the impact of alcohol.